Form 4: Twist Bio CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 4,887 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.
Summary
- Emily M. Leproust, CEO and Director of Twist Bioscience Corp (TWST), sold 4,887 shares of common stock on November 3, 2025.
- The shares were sold at a price of $32.0794 per share.
- This transaction was a non-discretionary 'sell to cover' sale, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
- Following this transaction, Ms. Leproust directly beneficially owns 733,922 shares of common stock.
- She also holds various employee stock options with exercise prices ranging from $5.95 to $67.85, subject to different vesting schedules and expiration dates.
Sentiment
Score: 7
Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is generally neutral to slightly positive as it indicates the vesting of equity awards. The CEO retains a substantial stake, showing continued alignment with shareholder interests.
Positives
- The sale was non-discretionary, indicating it was not a voluntary divestment by the CEO but rather a mandatory 'sell to cover' for tax purposes, which is a common practice for equity compensation.
- The CEO retains a significant beneficial ownership of 733,922 shares of common stock, demonstrating continued alignment with shareholder interests.
- The CEO holds substantial unexercised employee stock options, indicating potential future upside if the stock price increases.
Negatives
- A sale of shares by a key executive, even for tax purposes, can sometimes be misinterpreted by the market as a lack of confidence, though the filing clarifies its non-discretionary nature.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' for tax obligations, which is common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends for biotechnology or synthetic biology.
Comparison to Industry Standards
- The 'sell to cover' mechanism is a standard practice for managing tax liabilities on equity awards across publicly traded companies, aligning with common industry compensation practices.
Related Party Transactions
- The sale of shares to cover tax withholding obligations is a transaction mandated by the Issuer's equity incentive plans, making it a form of related party transaction between the executive and the company's plan administrator.
Stakeholder Impact
- Shareholders: The sale is non-discretionary and for tax purposes, so it should not be interpreted as a lack of confidence by the CEO. The CEO's continued significant ownership aligns her interests with shareholders.
- Employees: The vesting of Restricted Stock Units and subsequent tax-related sale is a standard part of executive compensation, which can be seen as a positive for employee retention and motivation through equity awards.
Key Dates
| Date | Description |
|---|---|
| 2016-09-01 | 25% of shares subject to an employee stock option (exercise price $5.95) vested, with 1/48th vesting monthly thereafter. |
| 2017-09-28 | 10% of shares subject to an employee stock option (exercise price $8.82) vested. |
| 2018-09-28 | 15% of shares subject to an employee stock option (exercise price $8.82) vested, with 1/48th vesting monthly thereafter. |
| 2019-10-31 | 20% of shares subject to an employee stock option (exercise price $26.66) vested and became exercisable, with 1/60th vesting monthly thereafter. |
| 2020-09-01 | Performance stock options (exercise price $67.85) granted to the reporting person. |
| 2020-10-24 | 25% of shares subject to an employee stock option (exercise price $23.33) vested, with 1/48th vesting monthly thereafter. |
| 2022-12-19 | Performance stock options (exercise price $67.85) vested and became exercisable due to meeting applicable performance criteria. |
| 2025-09-28 | Expiration date for an employee stock option (exercise price $5.95). |
| 2025-11-03 | Date of common stock transaction (sale for tax withholding). |
| 2025-11-05 | Signature date of the filing by Attorney-in-Fact. |
| 2027-09-28 | Expiration date for an employee stock option (exercise price $8.82). |
| 2028-11-18 | Expiration date for an employee stock option (exercise price $26.66). |
| 2029-10-23 | Expiration date for an employee stock option (exercise price $23.33). |
| 2030-08-31 | Expiration date for an employee stock option (exercise price $67.85). |
Recommendation
holdThis Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by the CEO for tax purposes, which is a common occurrence for executives receiving equity compensation. It does not reflect a change in the CEO's investment sentiment or the company's fundamentals. The CEO retains a substantial beneficial ownership, indicating continued alignment with shareholder interests. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis of the company's performance and market conditions.
Keywords
Twist Bioscience, TWST, Emily M. Leproust, CEO, Director, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Incentive Plan, Employee Stock Options, Biotechnology, Synthetic Biology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.